Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Last trade$20.00
Day change-$0.98 (-4.67%)
Day range$19.87 – $21.42
Volume103,293
Market cap$410M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$410.15M
Price / earnings
—
Price / book
1.79×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.84×
Profitability
Earnings per share
-$4.51
Return on assets
-36.13%
Return on equity
-38.42%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
19.71×
Quick ratio
19.71×
Cash ratio
19.39×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$69.33M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TECX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$6.02M
$6.17M
$6.43M
$5.18M
$4.96M
$5.15M
$5.26M
$4.84M
Research and development
$17.44M
$18.05M
$20.87M
$16.34M
$16.93M
$17.19M
$13.04M
$9.16M
Total operating expenses
$23.46M
$24.22M
$27.3M
$21.52M
$21.89M
$22.33M
$18.3M
$13.99M
Operating income
-$23.46M
-$24.22M
-$27.3M
-$21.52M
-$21.89M
-$22.33M
-$18.3M
-$13.99M
Interest expense
-$4K
-$6K
-$8K
-$12K
-$14K
-$17K
-$20K
-$22K
Income before taxes
-$21.35M
-$22.21M
-$25.24M
-$18.97M
-$19.04M
-$19.01M
-$15.91M
-$12.37M
Income taxes
$0
$77K
$0
$254K
$0
$976K
$0
$0
Net income
-$21.35M
-$22.29M
-$25.24M
-$19.23M
-$19.04M
-$19.98M
-$15.91M
-$12.37M
Net income attributable to common shareholders
-$21.35M
-$22.29M
-$25.24M
-$19.23M
-$19.04M
-$19.98M
-$15.91M
-$12.37M
EBITDA
-$23.21M
-$23.93M
-$27M
-$21.18M
-$21.55M
-$21.99M
-$17.94M
-$13.48M
Basic earnings per share
-$1.08
-$1.18
-$1.34
-$1.03
-$1.02
-$1.07
-$0.93
-$0.83
Diluted earnings per share
-$1.08
-$1.18
-$1.34
-$1.03
-$1.02
-$1.07
-$0.93
-$0.83
Recent news
Company coverage with links to the original publishers.
Biotechnology company Tectonic Therapeutic reported a wider Q2 2025 net loss of $20.0 million, driven by increased clinical trial activities for its lead drug TX45 targeting pulmonary hypertension. Despite higher expenses, the company maintains a strong cash position of $287.4 million, with runway projected into Q4 2028.
Tectonic Therapeutic announced positive results from a Phase 1b clinical trial of its lead asset TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF). The data confirmed TX45's tolerability and showed improvements in left ventricular function and pulmonary hemodynamics.
Tectonic Therapeutic announced positive results from the Phase 1a clinical trial of its lead asset, TX45, a long-acting, Fc-relaxin fusion protein. The results support further development of TX45 for the treatment of Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF).
Tectonic Therapeutic announced favorable Phase 1a results for its lead program TX45, a long-acting relaxin fusion protein, in the treatment of Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The results showed TX45 was well-tolerated with no observed immunogenicity and demonstrated a favorable PK/PD relationship, allowing for the identification of doses for the Phase 2 clinical trial.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.